// App-Quantinova.ai

9004 : Dacomitinib (daco) versus gefitinib (gef) for first-line treatment of advanced NSCLC (ARCHER 1050): Final overall survival (OS) analysis.

Researchers

Presenter

  • Tony Mok

Principal Investigators

  • Ying Cheng

  • Xiangdong Zhou

  • Ki Hyeong Lee

  • Kazuhiko Nakagawa

  • Seiji Niho

  • Min Young Lee

  • Rolf Gerhard Linke

  • Rafael Rosell

  • Jesus Corral Jaime

  • Maria Rita Migliorino

  • Adam Pluzanski

  • Eric I Sbar

  • Tao Wang

  • Jane Liang White

  • Yi-Long Wu

Medical Centers

  • Key Laboratory of South China, Department of Clinical Oncology, The Chinese University of Hong Kong, Hong Kong, China

  • Jilin Provincial Cancer Hospital, Changchun, China

  • First Affiliated Hospital of Third Military Medical University, Chongqing, China

  • Kindai University Hospital, Osaka, Japan

  • National Cancer Center, EPOC, Chiba, Japan

  • SFJ Asia Pacific, Singapore, Singapore

  • SFJ Pharmaceuticals Group, Pleasanton, CA

  • Catalan Institute of Oncology, Badalona, Spain

  • Hospital Universitario Virgen del Rocio, Sevilla, Spain

  • Pulmonary Oncology Unit, San Camillo-Forlanini Hospital, Rome, Italy

  • Maria Sklodowska-Curie Memorial Cancer Center & Institute of Oncology, Warsaw, Poland

  • Pfizer Inc, Collegeville, PA

  • Pfizer, Groton, CT

  • Guangdong Lung Cancer Institute, Guangdong General Hospital (GGH) and Guangdong Academy of Medical Sciences, Guangzhou, China

Locations

  • China

  • Japan

  • Italy

  • Singapore

  • Poland

  • Spain

  • United States

Companies

  • PharmAbcine Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • Epidermal growth factor receptor

  • Threonine at amino acid position 790

Drug/Treatment

  • dacomitinib

  • gefitinib

Outcome

  • N/A

Study Design

  • Randomized

Phase

  • III

Study Id's

  • NCT01774721

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved